Please login to the form below

Not currently logged in
Email:
Password:

David Horn Solomon takes the helm of Akari Therapeutics

He joins as its chief executive officer

Akari Therapeutics has appointed David Horn Solomon as its new chief executive officer, a role that will see him take the helm of the biopharma as it focuses on the development and commercialisation of orphan autoimmune and inflammatory disease treatments.

Ray Prudo, Akari's executive chairman, said: “I am very pleased that David will be joining Akari and that we have been successful in attracting a person of his calibre, with over 20 years of leadership experience in the biotechnology field.

“David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by Sanofi.”

His other roles have included CEO at Bionor Pharma and most recently he was at Nordic healthcare investment group Sund Capital where he was a managing partner.

Solomon, who will be based at the group’s headquarters in New York, said: “I am excited by Akari’s growing and diversified discovery platform and its clinical programmes in the complement mediated diseases.

“Akari is building momentum in its research programmes and this is a hugely exciting time to join and help advance its products.”

3rd October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics